Ignite Creation Date:
2024-05-06 @ 12:45 PM
Last Modification Date:
2024-10-26 @ 1:03 PM
Study NCT ID:
NCT03834623
Status:
COMPLETED
Last Update Posted:
2022-10-05
First Post:
2019-02-04
Brief Title:
Avadomide CC-122 in Combination With Nivolumab in Advanced Melanoma
Sponsor:
H Lee Moffitt Cancer Center and Research Institute
Organization:
H Lee Moffitt Cancer Center and Research Institute
Study Overview
Official Title:
A Phase II Biomarker Trial of Avadomide CC-122 in Combination With Nivolumab in Advanced Melanoma
Status:
COMPLETED
Status Verified Date:
2022-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is to find out if the combination of CC-122 an investigational agent and Nivolumab will enhance the anti-cancer activity and prevent T-cell exhaustion T-cells are responsible for maintaining the bodys immune response
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None